glp-1 coverage Who Gets the Shot? Access by State Coverage of Obesity Therapies in
Description
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children
Official supply shortages persisted for most of 2024, as surging demand for AOMs continued to outstrip product supply, despite limited reimbursement, which presented an opportunity quickly seized upon by U.S
A new Medicare program launching July 1 broadens access to drugs like Zepbound and Foundayo, but federal annuitants need to know how the $50 copay will affect their catastrophic limits.
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
